Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.63 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13983795 | 0.92 | FFAR4 (0.52) | FFAR4FFAR1LMNAPLA2G10GSTK1 | |
| SCHEMBL3901922 | 0.83 | GABRP (0.50) | FFAR4FFAR1KDM4CKDM4AKDM2A | |
| SCHEMBL5672920 | 0.83 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL4798381 | 0.83 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL8606372 | 0.83 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL15009701 | 0.83 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL2181858 | 0.83 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL5742369 | 0.83 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL22612709 | 0.83 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 | |
| SCHEMBL31650811 | 0.83 | FFAR4 (0.79) | FFAR4FFAR1LMNATSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7129366-B2 | Group of a novel anti-cancer compounds with specific structure | YANG'S BIOCHEM CO. LTD. (US) | 2006-10-31 | — | — | US | claimed |
| EP-1463707-A4 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | YANG ZHENHUA (US) | 2006-02-01 | — | — | EP | claimed |
| US-20040204599-A1 | Group of novel anti-cancer compounds with specific structure | YANG'S BIOCHEM CO. LTD. | 2004-10-14 | — | — | US | claimed |
| EP-1463707-A2 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | Yang, Zhenhua (US) | 2004-10-06 | — | — | EP | claimed |
| WO-2003014296-A2 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | YANG ZHENHUA (US) | 2003-02-20 | — | — | WO | claimed |
| CN-1343650-A | Anticancer compound with particular structure | YANG ZHENHUA (CN) | 2002-04-10 | — | — | CN | claimed |
| US-7129366-B2 | Group of a novel anti-cancer compounds with specific structure | YANG'S BIOCHEM CO. LTD. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1463707-A4 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | YANG ZHENHUA (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20040204599-A1 | Group of novel anti-cancer compounds with specific structure | YANG'S BIOCHEM CO. LTD. | 2004-10-14 | — | — | US | disclosed |
| EP-1463707-A2 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | Yang, Zhenhua (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003014296-A2 | A GROUP OF NOVEL ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE | YANG ZHENHUA (US) | 2003-02-20 | — | — | WO | disclosed |
| CN-1343650-A | Anticancer compound with particular structure | YANG ZHENHUA (CN) | 2002-04-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204599-A1 | Group of novel anti-cancer compounds with specific structure | FASN, NFKBIA, NFATC1 | FFAR4 109/4885FFAR1 82/4885KDM4C 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.